Biosensors International Group, which develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. today announced strong sales and earnings growth for its fourth fiscal quarter (4Q FY09) and fiscal year ended March 31, 2009 (FY09).

Total product sales in the fourth quarter were US$20.5 million ($29.75 million), a 75% increase over the same period a year ago (4Q FY08), driven largely by continued growth in the sales of BioMatrix drug‐eluting stents.

For FY09, total revenue was US$119 million, a 168% increase over FY08. Of this increase, US$40 million was a one‐time, non‐recurring payment received from Terumo Corporation to reduce future revenue sharing arrangements.

In 4Q FY09, the group reported a net profit of US$0.4 million compared to a net loss of US$20.7 million in 4Q FY08.

For FY09, the company reported a net loss of US$1.1 million compared to a net loss of US$31.6 million for FY08.

The company also reported significant gross margin improvement for its interventional cardiology products for both 4Q FY09 and FY09. Product gross margins were 65% for 4Q FY09, versus 36% for 4Q FY08, and 60% for FY09 versus 39% in FY08.

******************************************************************************************************************************************************************************************************************************************************

Would like to see their q-o-q figures. G Margin improvement for ICP but how much does the ICP account for total revenue? These are all headline numbers intended to thrill. Should look @revenue streams of product line especially the much touted stent. Overall they did eke out a profit which is well and good but wat is the forward guidance? anyone?